Filtered By:
Condition: Thrombosis
Procedure: Transplants
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 252 results found since Jan 2013.
Digoxin is Associated with Decreased Survival Free from Hemocompatibility-Related Adverse Events in LVAD Patients - A Propensity Score Matched Analysis
Hemocompatibility-related adverse events (HRAEs) (stroke, suspected pump thrombosis (sPT), gastrointestinal bleeding (GIB)) reduce survival and quality of life in LVAD pts. The association between pharmacotherapy and both HRAEs and survival is poorly characterized. We aimed to assess this association in HeartMate II (HMII) pts.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: A. Pinsino, A. Gaudig, K.L. Hoffman, D. D'Angelo, E.A. Royzman, G.M. Mondellini, F. Castagna, A.M. Zuver, A.R. Garan, H. Takayama, K. Takeda, Y. Naka, R.T. Demmer, M. Yuzefpolskaya, P.C. Colombo Tags: 397 Source Type: research
Mechanical Circulatory Support Patients Awaiting Heart Transplant with Positive AT1R Antibodies Have Acceptable Outcome Post-Heart Transplant
AT1R antibodies (Abs) are known to occur in patients (pts) with heart failure. It has been reported that when AT1R Abs are detected at high levels in mechanical circulatory support (MCS) pts, MCS mortality is increased. AT1R has been associated with the development of an inflammatory state inciting thrombosis. It may be that AT1R Abs are associated with pump thrombosis or even possibly thrombotic stroke. Furthermore, it is not clear whether these pts with MCS and AT1R Abs are at increased risk for post-heart transplant complications such as primary graft dysfunction (PGD) due to the recipients ’ highly inflamed state whi...
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: D.H. Chang, J. Patel, M. Kittleson, D. Geft, S. Dimbil, R. Levine, C. Kawata, L. Czer, J. Moriguchi, D. Ramzy, J.A. Kobashigawa Tags: 502 Source Type: research
Natural Antibodies and Left Ventricular Assist Device Complications
Left ventricular assist devices (LVAD) are widely used as a bridge to heart transplantation or destination therapy for advanced heart failure. However, hemocompatibility-related complications such as pump thrombosis, stroke and bleeding remain frequent. We previously reported that LVAD implantation is followed by a sharp increase in serum levels of IgG natural antibodies (Nabs) recognizing oxidation-specific epitopes (OSE). Nabs have been implicated in inflammatory reactions related to atherosclerosis, ischemic stroke and primary graft dysfunction following heart transplantation.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: S.B. See, A. Pinsino, N. Kunimune, D. Onat, E. Hittesdorf, A.R. Garan, V.K. Topkara, N. Yoshifumi, H. Takayama, K. Takeda, P.C. Colombo, G. Wagener, M. Yuzefpolskaya, E. Zorn Tags: 606 Source Type: research
The Implication of HeartWare HVAD Inflow Cannula Angle on Stroke and Thrombus Rate
Stroke and ventricular assist device (VAD) pump thrombus are serious complications that have previously been thought to be related to surgical placement - namely VAD inflow cannula angle. Our aim with this study was to better elucidate the impact of post-operative HeartWare HVAD (left VAD) cannula inflow angle on stroke and thrombus rate within a single centre in Sydney, Australia.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: S. Emmanuel, D. Aktuerk, A. Chowdhury, C. Hurwitz, L. Beiglari, P. Jansz, C. Hayward Tags: 1080 Source Type: research
Cardiovascular disease after childhood acute lymphoblastic leukaemia: a cohort study.
CONCLUSIONS: Despite attempts to reduce cardiotoxicity in childhood cancer treatment, CVD risks in ALL survivors treated more recently do not seem to have declined.
PMID: 30852834 [PubMed - in process]
Source: Swiss Medical Weekly - February 24, 2019 Category: General Medicine Authors: Hau EM, Caccia JN, Kasteler R, Spycher B, Suter T, Ammann RA, von der Weid NX, Kuehni CE Tags: Swiss Med Wkly Source Type: research
Mechanical circulatory support in the heart failure population
Purpose of review
Use of durable left ventricular assist devices (LVADs) has increased considerably in recent years because of the insufficient supply of donor hearts for cardiac transplantation and improvement in outcomes from refinements in technology. This review examines clinical utility of these devices and summarizes the most recent evidence supporting the use of LVAD therapy.
Recent findings
There continues to be significant advancements made in LVAD technology, which has resulted in improvements in the rates of adverse events and overall patient quality of life. Specifically, less invasive and improved surgica...
Source: Current Opinion in Cardiology - February 6, 2019 Category: Cardiology Tags: HEART FAILURE: Edited by Haissam Haddad Source Type: research
Bridging Therapy Versus Direct Mechanical Thrombectomy in Patients with Acute Ischemic Stroke due to Middle Cerebral Artery Occlusion: A Clinical-Histological Analysis of Retrieved Thrombi.
In conclusion, there was no difference in the functional outcomes between the direct MT and bridging therapy groups. However, randomized trials are needed to elucidate the high ratio of cardioembolism subtype in our group of patients. The histological MCA thrombus composition differed between cardioembolism and large-artery atherosclerosis, and this finding provides valuable information on the underlying pathogenesis and thrombus origin.
PMID: 30654640 [PubMed - as supplied by publisher]
Source: Cell Transplantation - January 18, 2019 Category: Cytology Authors: Gong L, Zheng X, Feng L, Zhang X, Dong Q, Zhou X, Wang H, Zhang X, Shu Z, Zhao Y, Liu X Tags: Cell Transplant Source Type: research
KLF11 (Kru üppel-Like Factor 11) Inhibits Arterial Thrombosis via Suppression of Tissue Factor in the Vascular Wall.
Conclusions- Our data demonstrate that KLF11 is a novel transcriptional suppressor of F3 in vascular smooth muscle cells, constituting a potential molecular target for inhibition of arterial thrombosis.
PMID: 30602303 [PubMed - as supplied by publisher]
Source: Arteriosclerosis, Thrombosis and Vascular Biology - January 3, 2019 Category: Cardiology Authors: Liang W, Fan Y, Lu H, Chang Z, Hu W, Sun J, Wang H, Zhu T, Wang J, Adili R, Garcia-Barrio MT, Holinstat M, Eitzman D, Zhang J, Chen YE Tags: Arterioscler Thromb Vasc Biol Source Type: research
Description of the First Cases with ADAMTS13 Mutations in Hungary
CONCLUSIONS:Clinical and molecular characterization of the first 5 Hungarian cases with ADAMTS13 mutations was presented. Compound heterozygous, damaging ADAMTS13 mutations with deficient plasma ADAMTS13 activity were associated with serious clinical consequences. In case of thrombotic microangiopathy in young patients with stroke, or HELLP syndrome, complete workup for ADAMTS13 activity and inhibitors is necessary, and genetic analysis should be considered. Three new ADAMTS13 mutations (c.1016_1017delCA, c.3199T>A , c.2839C>T) were identified and shown to be associated with decreased plasma ADAMTS13 activity.Disclos...
Source: Blood - November 21, 2018 Category: Hematology Authors: Reti, M., Sinkovits, G., Cseprekal, O., Csuka, D., Szilagyi, A., Farkas, Z., Klucsik, Z., Szederjesi, A., Wagner, L., Reusz, G., Kremer Hovinga, J. A., Rigo, J., Masszi, T., Prohaszka, Z. Tags: 311. Disorders of Platelet Number or Function Source Type: research
Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy
ConclusionsIn this pilot study of 50 patients, low-dose apixaban was safe and well tolerated as thromboprophylaxis for patients with MM receiving IMiDs. No patients experienced VTE, major hemorrhage, stroke, or MI. Further randomized studies are needed to validate apixaban as a standard primary prevention anti-thrombotic strategy for patients with MM receiving IMiDs.DisclosuresMoslehi: Bristol-Myers Squibb: Consultancy, Research Funding. Jagasia: Incyte Corporation: Membership on an entity's Board of Directors or advisory committees.
Source: Blood - November 21, 2018 Category: Hematology Authors: Cornell, R. F., Goldhaber, S. Z., Engelhardt, B. G., Moslehi, J., Jagasia, M., Patton, D., Harrell, S. L., Hall, R. L., Wyatt, H., Piazza, G. Tags: 332. Antithrombotic Therapy: Poster I Source Type: research
Prognostic implications of serial outpatient blood pressure measurements in patients with a left ventricular assist device
Elevated blood pressure (BP) has been linked to adverse events during left ventricular assist device support. We aimed to investigate the association between outpatient BP and stroke or suspected pump thrombosis among HeartMate II (HMII) recipients.
Source: The Journal of Heart and Lung Transplantation - November 15, 2018 Category: Transplant Surgery Authors: Alberto Pinsino, Francesco Castagna, Amelia M Zuver, Eugene A Royzman, Mojdeh Nasiri, Eric J St öhr, Barbara Cagliostro, Barry McDonnell, John R Cockcroft, A Reshad Garan, Veli K Topkara, P Christian Schulze, Koji Takeda, Hiroo Takayama, Yoshifumi Naka, Tags: Original Clinical Science Source Type: research
Prognostic implications of serial outpatient blood pressure measurements in patients with an axial continuous-flow left ventricular assist device
In this study we investigated the association between outpatient BP and stroke or suspected pump thrombosis among HeartMate II (HMII) recipients.
Source: The Journal of Heart and Lung Transplantation - November 15, 2018 Category: Transplant Surgery Authors: Alberto Pinsino, Francesco Castagna, Amelia M. Zuver, Eugene A. Royzman, Mojdeh Nasiri, Eric J. St öhr, Barbara Cagliostro, Barry McDonnell, John R. Cockcroft, A. Reshad Garan, Veli K. Topkara, P. Christian Schulze, Koji Takeda, Hiroo Takayama, Yoshifumi Tags: ORIGINAL CLINICAL SCIENCE Source Type: research
Abbott & #039;s HeartMate 3 Pump Can Now be Offered as a Destination Therapy
As if Abbott Laboratories hasn't had enough to celebrate this year, the company just scored FDA approval for the use of its Heartmate 3 pump as a destination therapy. The approval, which CEO Miles White hinted about earlier in the week, is a big win for Abbott – and an even bigger win for advanced heart failure patients.
The approval means that doctors can now offer the HeartMate 3 system to patients who are not eligible for a transplant. These patients will live with the device for the rest of their lives.
For advanced heart failure patients who can no longer rely on earlier stage treatment o...
Source: MDDI - October 19, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Business Source Type: news
FDA approves Abbott ’ s HeartMate 3 as a destination therapy
Abbott (NYSE:ABT) said today it won FDA approval for its HeartMate 3 left ventricular assist device, now approved as a destination therapy for patients with advanced heart failure.
With the approval, the Chicago-based company said that the device can now be used in patients not eligible for a transplant as a life-long implant.
“We partner with physicians to holistically develop therapies that benefit patients and achieve better outcomes. The unique design of the HeartMate 3 LVAD—with its Full MagLev technology—takes an established innovation and improves upon it in meaningful ways to help people with advanced he...
Source: Mass Device - October 19, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Food & Drug Administration (FDA) Regulatory/Compliance Abbott Source Type: news
Factors Associated with Prolonged Survival in Left Ventricular Assist Device Recipients
ConclusionsPreoperative diabetes and amiodarone use were associated with poor long-term survival in LVAD recipients. Development of early complications of stroke, gastrointestinal bleeding, hemolysis, or pump thrombosis was also associated with poor long-term survival. Early diagnosis and treatment of these complications may improve survival in LVAD recipients.
Source: The Annals of Thoracic Surgery - October 12, 2018 Category: Cardiovascular & Thoracic Surgery Source Type: research
